Teva Announces Positive Results from a Phase III Study for QNAZE

Teva Pharmaceutical Industries Ltd. TEVA today announced results from a Phase III study of QNAZE HFA, its nasal aerosol corticosteroid in development for the treatment of perennial allergic rhinitis and seasonal allergic rhinitis. Results of the study evaluating patients with PAR showed the once-daily, non-aqueous formulation achieved all primary and secondary efficacy endpoints, demonstrating significantly greater relief of nasal symptoms, including runny nose, nasal congestion, nasal itching and sneezing, compared with placebo. Consistent with previous studies, the product demonstrated safety similar to placebo.